Three-year follow-up of bintrafusp alfa, a bifunctional fusion protein targeting TGF-beta and PD-L1, for second-line (2L) treatment of non-small cell lung cancer (NSCLC)

Simple item page
dc.conference.dateSEP 19-OCT 18, 2020
dc.conference.titleESMO Virtual Congress
dc.contributor.authorPaz-Ares, L.
dc.contributor.authorKim, T. M.
dc.contributor.authorVicente, D.
dc.contributor.authorFelip, E.
dc.contributor.authorLee, D. H.
dc.contributor.authorLee, K. H.
dc.contributor.authorLin, C-C.
dc.contributor.authorFlor, M. J.
dc.contributor.authorDi Nicola, M.
dc.contributor.authorAlvarez, R. M.
dc.contributor.authorHelwig, C.
dc.contributor.authorOjalvo, L. S.
dc.contributor.authorGulley, J.
dc.contributor.authorCho, B. C.
dc.contributor.authoraffiliation[Paz-Ares, L.] Hosp Univ 12 Octubre, Med Oncol, Madrid, Spain
dc.contributor.authoraffiliation[Kim, T. M.] Seoul Natl Univ Hosp, Dept Internal Med, Seoul, South Korea
dc.contributor.authoraffiliation[Vicente, D.] Hosp Univ Virgen Macarena, Med Oncol, Seville, Spain
dc.contributor.authoraffiliation[Felip, E.] Hosp Univ Vall dHebron, Med Oncol, Barcelona, Spain
dc.contributor.authoraffiliation[Lee, D. H.] Univ Ulsan, Coll Med Seoul, Asan Med Ctr, Seoul, South Korea
dc.contributor.authoraffiliation[Lee, K. H.] Chungbuk Natl Univ Hosp, Internal Med, Cheongju, Chungcheongbuk, South Korea
dc.contributor.authoraffiliation[Lin, C-C.] Natl Taiwan Univ Hosp, Dept Oncol, Taipei, Taiwan
dc.contributor.authoraffiliation[Flor, M. J.] Hosp Univ Virgen del Rocio, Serv Oncol Med, Seville, Spain
dc.contributor.authoraffiliation[Di Nicola, M.] Fdn IRCCS Ist Nazl Tumori, Unit Immunotherapy & Anticancer Innovat Therapeut, Milan, Italy
dc.contributor.authoraffiliation[Alvarez, R. M.] Gregorio Maranon Hosp, Med Oncol, Madrid, Spain
dc.contributor.authoraffiliation[Helwig, C.] Merck KGaA, Biostat, Darmstadt, Germany
dc.contributor.authoraffiliation[Ojalvo, L. S.] EMD Serono Res & Dev Inst Inc, Global Clin Dev, Billerica, MA USA
dc.contributor.authoraffiliation[Gulley, J.] NCI, Genitourinary Malignancies Branch, NIH, Bethesda, MD 20892 USA
dc.contributor.authoraffiliation[Cho, B. C.] Yonsei Univ, Coll Med, Yonsei Canc Ctr, Med Oncol, Seoul, South Korea
dc.contributor.funderMerck, KGaA, Darmstadt, Germany
dc.contributor.funderGlaxoSmithKline
dc.date.accessioned2025-01-07T16:00:22Z
dc.date.available2025-01-07T16:00:22Z
dc.date.issued2020-09-01
dc.identifier.doi10.1016/j.annonc.2020.08.1586
dc.identifier.essn1569-8041
dc.identifier.issn0923-7534
dc.identifier.unpaywallURLhttp://www.annalsofoncology.org/article/S0923753420415820/pdf
dc.identifier.urihttps://hdl.handle.net/10668/27552
dc.identifier.wosID573469101558
dc.issue.number4
dc.journal.titleAnnals of oncology
dc.journal.titleabbreviationAnn. oncol.
dc.language.isoen
dc.organizationSAS - Hospital Universitario Virgen del Rocío
dc.organizationSAS - Hospital Universitario Virgen Macarena
dc.page.numberS822-S822
dc.publisherElsevier
dc.rights.accessRightsopen access
dc.titleThree-year follow-up of bintrafusp alfa, a bifunctional fusion protein targeting TGF-beta and PD-L1, for second-line (2L) treatment of non-small cell lung cancer (NSCLC)
dc.typeconference output
dc.type.hasVersionVoR
dc.volume.number31
dc.wostypeMeeting Abstract

Files

Collections

SAS - Hospital Universitario Virgen del Rocío
SAS - Hospital Universitario Virgen Macarena

© 2023 – Repositorio Institucional de Salud de Andalucía - Fundación Pública Andaluza Progreso y Salud - Consejería de Salud y Consumo de la Junta de Andalucía